I believe the dual listing is to access capital in Europe. There is a lot of options for Recce going forward if they get FDA approval. I find it hard to believe that they would go it alone. More likely they will license other pharma to produce and distribute or we will get bought out well before that stage. High level of insider ownership will be able to block any token effort at a takeover. Anyway dare to dream. That is all several years away
RCE Price at posting:
83.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)